Form 144 RELAY THERAPEUTICS INC For: 18 November By Investing.com
This article announces the filing of Form 144 for RELAY THERAPEUTICS INC (RLAY) on November 18, 2026. Form 144 is a notice of the intent to sell restricted stock. The article provides minimal details beyond the filing announcement and the stock's performance on that day (-3.63%).
Form 144 RELAY THERAPEUTICS INC For: 18 November By Investing.com
Investing.com reported on a Form 144 filing for RELAY THERAPEUTICS INC, specifically pertaining to November 18. The article, published on November 18, 2026, focuses on this financial disclosure, offering only the title and the company ticker RLAY in its content.
SoftBank reports shared ownership of 21.9M shares in Relay Therapeutics (RLAY).
SoftBank entities, including SB Investment Advisers (UK) Limited, SoftBank Vision Fund (AIV M2) L.P., and SVF Pauling (Cayman) Limited, have reported a shared beneficial ownership of 21,904,963 shares in Relay Therapeutics, Inc. (RLAY). This stake represents 9.9% of the common stock outstanding as of September 30, 2026. The disclosure was made via a SCHEDULE 13G/A filing with the SEC.
Late Stage Trial Focus Could Be A Game Changer For Relay Therapeutics (RLAY)
Relay Therapeutics reported significant net losses in Q3 2026 and for the first nine months of the year, but the company is heavily investing in late-stage oncology and vascular anomaly programs, including Phase 3 trials. The investment narrative focuses on these pipeline advancements, particularly the Phase 3 ReDiscover 2 trial for zovegalisib, as key catalysts for future commercialization and potential upside despite current losses. Analysts are closely watching execution on these programs and disciplined capital use to assess the company's long-term potential.
Jones Trading maintains Relay Therapeutics at Buy, raises price target to $31 from $20
Jones Trading has reaffirmed its "Buy" rating for Relay Therapeutics (RLAY) and increased its price target to $31 from $20, marking a 55% jump. This new price target suggests a potential upside of 66.7% from the stock's closing price of $18.60 on November 6. Investors can find further details on price target data and analyst recommendations on TradingView's platform.
Relay Therapeutics (RLAY) Could Be 38% Undervalued On Q3 Earnings And Pipeline Progress
Relay Therapeutics (RLAY) reported wider losses in Q3 2026 but provided updates on its late-stage cancer pipeline and commercialization efforts, leading to mixed market reactions despite a year-to-date gain of 107.82%. The stock is considered 38% undervalued by analysts, with a fair value target of $27.58, contingent on the success of its zovegalisib trials. Investors are advised to consider both the potential rewards and risks, particularly concerning the pivotal trials and regulatory support for accelerated paths.
How Wider Q3 Losses Will Impact Relay Therapeutics Stock Investors
Relay Therapeutics reported wider Q3 2026 net losses of US$81.75 million and lower revenue compared to the prior year, with a nine-month net loss of US$238.74 million. Despite increased absolute losses, the loss per share narrowed, suggesting improved cost efficiency while the company continues heavy investment in its pipeline, particularly the zovegalisib franchise. The company's investment narrative hinges on its precision oncology pipeline eventually justifying current expenditures, with key catalysts being the Phase 3 ReDiscover 2 trial and progress in PI3Kα driven vascular anomalies.
Relay Therapeutics, Inc. (RLAY) Tops Q3 EPS by 3c
Relay Therapeutics, Inc. (NASDAQ: RLAY) reported its Q3 earnings per share (EPS), which came in at ($0.37). This figure exceeded analyst estimates by $0.03, as analysts had projected an EPS of ($0.40). The stock price for RLAY was $18.03, showing a gain of 3.38% on the day.
Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
Relay Therapeutics reported its third-quarter 2026 financial results, highlighting the swift enrollment in its Phase 3 ReDiscover-2 trial for second-line breast cancer and upcoming data presentation for zovegalisib in vascular anomalies at the ASH Annual Meeting. The company also announced Shannon Campbell as the new Head of Commercial and a new research program for a mutant-selective TIE2 inhibitor. Financially, Relay Therapeutics holds approximately $849 million in cash, cash equivalents, and investments, projected to fund operations into 2029.
Earnings to Watch: Relay Therapeutics Inc (RLAY) Q3 2026 -- GF Value Sees 65% Downside
Relay Therapeutics Inc (NASDAQ:RLAY) is preparing to release its Q3 2026 earnings on November 4, 2026, with analysts forecasting $0.24 million in revenue and an earnings per share of -$0.40. While revenue estimates for the full year 2026 have slightly declined, those for 2027 have increased significantly. Despite an average analyst price target suggesting a 57.83% upside, GuruFocus's GF Value indicates a potential downside of 65.28%.
Three November talks from Relay Therapeutics will stream live
Relay Therapeutics (Nasdaq: RLAY) announced that its management will participate in three investor conferences in November 2026, featuring fireside chats. The events include the Guggenheim 3rd Annual Healthcare Innovation Conference, UBS Global Biopharma Conference 2026, and Jefferies Global Healthcare Conference. Live webcasts and archived replays will be available on the company's website.
Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November
Relay Therapeutics, Inc. (Nasdaq: RLAY) announced its participation in three investor conferences in November 2026, including the Guggenheim 3rd Annual Healthcare Innovation Conference, UBS Global Biopharma Conference 2026, and Jefferies Global Healthcare Conference. Management will hold fireside chats at these events, which will be webcast live on the company's website. Relay Therapeutics is a clinical-stage precision medicine company focused on developing therapies for cancer and genetic diseases.
Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November
Relay Therapeutics, Inc. (Nasdaq: RLAY) announced its participation in three investor conferences in November 2026, including the Guggenheim 3rd Annual Healthcare Innovation Conference, UBS Global Biopharma Conference 2026, and Jefferies Global Healthcare Conference. Management will hold fireside chats at these events, which will be webcast live on the company's website. Relay Therapeutics is a clinical-stage precision medicine company focused on developing therapies for cancer and genetic diseases.
Relay Therapeutics, Inc. (RLAY) Seasonal returns chart
This article from Yahoo Finance presents the seasonal returns chart for Relay Therapeutics, Inc. (RLAY). It displays the average monthly price return for the company's stock from 2020 to 2026, offering insights into its historical seasonality. The page also provides current stock information, including its real-time price and after-hours trading data.
To cover taxes, Relay Therapeutics (RLAY) R&D president sells 2,252 shares.
Donald A. Bergstrom, President of R&D at Relay Therapeutics (RLAY), sold 2,252 shares of common stock at $18.62 per share on October 28, 2026. This sale was conducted to cover income tax withholding obligations following the vesting of 5,012 restricted stock units on October 27, 2026. After the transaction, Bergstrom holds 396,878 shares.
A 753-share sale covers stock-vesting taxes at Relay Therapeutics (RLAY).
Peter Rahmer, Chief Corporate Development Officer at Relay Therapeutics (RLAY), sold 753 shares of common stock at $18.62 each on October 28, 2026. This sale was non-discretionary and intended to cover income tax withholding obligations arising from the vesting of 3,051 restricted stock units (RSUs) on October 27, 2026. Following the transaction, Rahmer directly held 222,904 shares, including shares underlying RSUs.
Form 4 Relay Therapeutics Inc: Peter Rahmer (Officer) For: 28 October By Investing.com
This article reports on a Form 4 filing for Relay Therapeutics Inc., indicating a transaction by officer Peter Rahmer on October 28th. The filing was published by Investing.com on October 31, 2026, at 02:20 am. The article includes a stock symbol RLAY and a current performance of -5.75%.
Peter Rahmer Sells 753 Relay Therapeutics Shares at $18.62 to Cover RSU Tax Withholding
Peter Rahmer, Chief Corporate Development Officer at Relay Therapeutics, Inc. (NASDAQ:RLAY), sold 753 common shares on October 28, 2026, at $18.62 per share. This transaction was conducted to cover tax withholding obligations following the vesting of 3,051 restricted stock units on October 27, 2026. Rahmer's post-transaction ownership stands at 222,904 shares, including those underlying RSUs, with the sale being non-discretionary per company policy.
Form 4 Relay Therapeutics Inc: Peter Rahmer (Officer) For: 28 October
This article reports on a Form 4 filing for Relay Therapeutics Inc, indicating an insider transaction involving Peter Rahmer (Officer) on October 28. The brief update was published on Investing.com. It provides no further details on the nature of the transaction.
Relay Therapeutics to Report Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026
Relay Therapeutics, Inc. (Nasdaq: RLAY) will release its third quarter 2026 financial results and corporate updates on November 4, 2026, after the U.S. market close. The company, which focuses on precision medicines for cancer and genetic diseases using its Dynamo® platform, has its lead candidate, zovegalisib, in a Phase 3 trial for HR+/HER2- metastatic breast cancer and is also exploring it for PI3Kα-driven vascular anomalies. The report is expected to provide transparency to investors and highlight progress in their clinical development pipeline.
Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026
Relay Therapeutics, Inc. (Nasdaq: RLAY) announced that it will report its third-quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Wednesday, November 4, 2026. The company is a clinical-stage precision medicine company focused on developing therapies for cancer and genetic diseases, utilizing its Dynamo® platform. Its lead clinical asset, zovegalisib, is in a Phase 3 trial for metastatic breast cancer and is also being investigated for PI3Kα-driven vascular anomalies.
Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026
Relay Therapeutics, Inc. (Nasdaq: RLAY) will announce its third quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Wednesday, November 4, 2026. The company is a clinical-stage precision medicine firm focused on developing therapies for cancer and genetic diseases, utilizing its Dynamo® platform. Its lead clinical asset, zovegalisib, is currently in a Phase 3 trial for metastatic breast cancer and is also being investigated for PI3Kα-driven vascular anomalies.
Guggenheim Initiates Relay Therapeutics(RLAY.US) With Buy Rating, Announces Target Price $26
Guggenheim has initiated coverage on Relay Therapeutics (RLAY.US) with a Buy rating. The firm has set a price target of $26 for the biopharmaceutical company. This new rating suggests a positive outlook from Guggenheim on Relay Therapeutics' future performance.
Relay Therapeutics, Inc. Estimates – NASDAQ:RLAY
This page on TradingView provides financial estimates and actuals for Relay Therapeutics, Inc. (NASDAQ: RLAY). Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with average, high, and low estimates, and visualizing trends over time. The information is available on both an annual and quarterly basis.
Relay Therapeutics stock: Bank of America maintains a USD 25.00 target for Relay Therapeutics stock
Bank of America has maintained a Buy rating and a USD 25.00 target for Relay Therapeutics (RLAY) stock, despite the company reporting second-quarter revenue of USD 0.35 million, below the USD 0.96 million expected. The clinical-stage biotechnology company's valuation is heavily tied to its development progress, with a market capitalization of USD 4.0 billion and a 52-week range of USD 5.95 to USD 21.27 as of October 23, 2026. The analyst consensus, though numerically constructive, shows a spread in targets, with MarketBeat citing a USD 25.92 average.
H.C. Wainwright raises target for Relay Therapeutics stock to USD 29
H.C. Wainwright has raised its target for Relay Therapeutics (RLAY) stock to USD 29, maintaining a Buy rating, despite the company's second-quarter earnings miss. The biotech firm, with a market capitalization of USD 3.8 billion, holds USD 911 million in cash, which is expected to fund operations until 2029 and supports its pipeline of three registrational programs, including a planned Phase 3 breast cancer trial. The valuation remains subject to clinical trial success, regulatory approvals, and product commercialization, as near-term sales are still distant.
Relay Therapeutics officer proposes USD 1.81 million sale for Relay Therapeutics stock
An officer at Relay Therapeutics, Thomas Catinazzo, has proposed selling 93,153 shares of company stock, valued at $1.81 million. This proposed sale comes as the company reports $911 million in cash, sufficient to fund operations into 2029, with upcoming milestones in their breast cancer and vascular anomalies programs. Analysts maintain "Buy" ratings with price targets between $26.00 and $29.00 for RLAY.
Analysts Are Bullish on Top Healthcare Stocks: Alvotech (ALVO), Relay Therapeutics (RLAY)
Analysts are showing bullish sentiment towards several healthcare stocks, including Alvotech (ALVO), Relay Therapeutics (RLAY), and AgomAb Therapeutics NV ADR (AGMB). Bank of America Securities maintained Buy ratings on Alvotech and Relay Therapeutics with price targets of $7.00 and $25.00 respectively. Morgan Stanley also maintained a Buy rating on AgomAb Therapeutics with a $28.00 price target, highlighting significant upside potential.
Form 144 RELAY THERAPEUTICS INC For: 11 October By Investing.com
This article announces the filing of Form 144 for RELAY THERAPEUTICS INC on October 11, 2026. The content is brief, primarily serving as a notification about this financial filing. It includes the stock symbol RLAY and a minor percentage change for the stock.
Form 144 RELAY THERAPEUTICS INC For: 11 October By Investing.com
This article from Investing.com announces the filing of Form 144 for RELAY THERAPEUTICS INC (RLAY) on October 11, 2026. Form 144 is typically filed by insiders planning to sell restricted stock. The brief piece includes the stock symbol and its current performance (+2.70%).
Form 144 RELAY THERAPEUTICS For: 10 October By Investing.com
This article from Investing.com announces the filing of Form 144 for RELAY THERAPEUTICS on October 10th. Form 144 is a notice of the intent to sell restricted securities. The article provides this basic announcement along with various market data and other news.
Relay Therapeutics CEO Sanjiv Patel sells $872,401 company stock
Relay Therapeutics CEO Sanjiv Patel sold 48,199 shares of company stock on October 7, 2026, totaling $872,401. This transaction was part of a Rule 10b5-1 trading plan and occurred after a significant price surge for the stock. Analysts currently view the stock as overvalued, despite several firms maintaining "Buy" ratings and raising price targets due to progress in breast cancer treatment development.
Relay Therapeutics CFO Catinazzo sells $329k in shares
Relay Therapeutics CFO Thomas Catinazzo sold 17,717 shares of the company's common stock for approximately $329,321 on October 6, 2026, under a pre-arranged trading plan. Despite the stock's 185% surge over the past year, InvestingPro analysis indicates it is overvalued. This insider sale follows a period of significant analyst interest and positive ratings for Relay Therapeutics, particularly concerning its lead asset, zovegalisib.
Form 4 Relay Therapeutics Inc For: 8 October By Investing.com
This article reports on the filing of Form 4 for Relay Therapeutics Inc. on October 8. Form 4 filings are used to disclose changes in beneficial ownership of a company's securities by insiders. The article includes the stock symbol RLAY and indicates a minor price movement.
Under a trading plan, Relay Therapeutics (RLAY) CFO sells 17,511 shares plus 206 more.
Relay Therapeutics CFO Thomas Catinazzo sold a total of 17,717 shares of RLAY common stock on October 6, 2026, under a Rule 10b5-1 trading plan. The shares were sold in two separate transactions at weighted average prices of $18.58 and $19.26 per share, respectively. These sales amounted to approximately $329,000 and were executed in multiple trades within specified price ranges.
CEO sells 48,199 shares under a trading plan at Relay Therapeutics (RLAY).
Sanjiv Patel, President and CEO of Relay Therapeutics (RLAY), sold 48,199 common shares on October 7, 2026, at a weighted average price of $18.10 per share. This sale was conducted under a Rule 10b5-1 trading plan established on October 30, 2025. After the transaction, Patel directly held 471,301 shares, while disclaiming beneficial ownership of additional shares held in two family trusts.
Relay Therapeutics (RLAY) Pullback Puts Its Vascular Anomalies Valuation Narrative To The Test
Relay Therapeutics (RLAY) has seen a recent stock pullback following strong year-to-date performance, leading investors to question if its valuation narrative still holds. The company is considered 35% undervalued with a fair value estimate of $27.58, primarily driven by its late-stage oncology and vascular anomalies programs, particularly zovegalisib's potential in PI3Kα driven vascular anomalies. However, the article highlights risks related to clinical trial outcomes and regulatory approvals that could impact this narrative.
Relay Therapeutics (RLAY) Pullback Puts Its Vascular Anomalies Valuation Narrative To The Test
Relay Therapeutics (RLAY) has seen a significant pullback in its stock price recently, despite strong year-to-date performance. The company is currently considered 35% undervalued with a fair value estimate of $27.58, primarily driven by its late-stage oncology and vascular anomaly programs, especially the potential of zovegalisib for PI3Kα driven vascular anomalies. However, the valuation depends on the success of Phase 3 trials and regulatory approval, with potential risks if these pathways encounter setbacks.
Relay Therapeutics Insider Sold Shares Worth $329,322, According to a Recent SEC Filing
Relay Therapeutics' Chief Financial Officer, Thomas Catinazzo, sold 17,717 shares of the company's stock on October 6, 2026. The transaction was valued at $329,322, according to a recent SEC filing. The article indicates that full details are available to premium subscribers.
After two share sales, Sanjiv Patel proposes another at Relay Therapeutics (RLAY).
Sanjiv Patel, associated with Relay Therapeutics (RLAY), has proposed selling 96,401 common shares valued at $1,806,554.74. This proposed sale, expected around October 7, 2026, follows two previous 10b5-1 sales of 48,199 shares each in August and September 2026. The shares originated from restricted stock units acquired on February 10, 2025.
PERCEPTIVE ADVISORS LLC's Relay Therapeutics Inc(RLAY) Holding History
This article details PERCEPTIVE ADVISORS LLC's historical holdings in Relay Therapeutics Inc (RLAY). As of June 30, 2026, the firm holds 14.11 million shares valued at $263.93 million, representing 3.97% of its portfolio and 6.44% of RLAY's outstanding stock. Based on transactions since Q3 2020, PERCEPTIVE ADVISORS LLC has an estimated gain of $35.67 million on its RLAY holdings.
After two 17,717-share sales, a Relay Therapeutics (RLAY) officer proposes another sale.
Relay Therapeutics (RLAY) officer Thomas Catinazzo has proposed selling 93,153 common shares, valued at approximately $1.81 million, with an anticipated sale date of October 6, 2026. This proposed sale follows two prior 10b5-1 sales in September and August 2026, each for 17,717 shares. The shares proposed for sale were acquired through the vesting of restricted and performance stock units between January 2025 and January 2026.
Relay Therapeutics stock fell 3.35 percent as officer filed to sell shares
Relay Therapeutics (RLAY) stock dropped 3.35% after an officer filed to sell 93,153 shares valued at over $1.8 million. This insider selling activity, combined with a Q2 revenue miss, created a supply signal for investors. Despite analyst targets suggesting a significant upside, the stock remains below its yearly high.
Possible Bearish Signals With Relay Therapeutics Insiders Disposing Stock
This article examines recent insider selling at Relay Therapeutics (NASDAQ:RLAY), where executives and directors have disposed of a significant amount of stock over the last year. Despite a strong financial performance shown in the latest quarterly report, the consistent selling could be interpreted as a bearish signal, suggesting that insiders might believe the stock is overvalued or that future growth may not meet expectations. The analysis highlights the importance of observing insider transaction patterns as an indicator of potential future stock performance.
RLAY: Relay Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas
Relay Therapeutics Inc. (RLAY) is experiencing downward pressure on its stock, with a recent 8% drop and an additional 1.5% decline, attributed to post-earnings news and trial updates. The company, which focuses on small molecule therapeutic discovery in targeted oncology using its Dynamo platform, is valued at a market cap of $4.25 billion. Investors are advised to use defined-risk strategies due to expected headline-driven moves, especially with the Phase 3 trial for zovegalisib commencing and a recent earnings miss.
JonesTrading Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $20
JonesTrading has reiterated its Buy rating for Relay Therapeutics (RLAY.US) and maintained its price target at $20. This indicates the firm's continued confidence in the company's stock performance.
Relay Therapeutics Stock In Focus As Phase 3 Trial Begins
Relay Therapeutics has initiated a Phase 3 clinical trial for zovegalisib (RLY-2608), a PI3Ka inhibitor developed in collaboration with X-Chem. This progression into a late-stage trial highlights Relay Therapeutics' strategy of leveraging external discovery platforms to advance its oncology pipeline and share development risks. The company's investment narrative now focuses on how this drug's advancement will impact its financial outlook, with analysts forecasting significant revenue growth despite current unprofitability.
Brenton Mar: Reflecting on Transformative Journey in Cancer Drug Development at Relay Therapeutics
Brenton Mar, former Senior Vice President of Clinical Development at Relay Therapeutics, reflected on his 3.5 transformative years at the company. During his tenure, Relay Therapeutics developed two FDA Breakthrough Designated drugs: lirafugratinib for cholangiocarcinoma and zovegalisib for breast cancer, and achieved proof of concept for zovegalisib in vascular malformations, along with advancing RLY-8161 for NRAS-mutant solid tumors. Mar expressed gratitude to his colleagues and shared his excitement for his next venture in the biotech world.
X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics
X-Chem announced a significant milestone in its collaboration with Relay Therapeutics, as Relay initiated a Phase 3 clinical trial for zovegalisib (RLY-2608). This drug candidate originated from a compound identified through X-Chem's DNA-encoded chemical library (DEL) screen, targeting PI3Ka for breast cancer treatment. Both companies highlighted the success of their collaboration and the differentiated pharmacology of the discovered compound.
Relay Therapeutics stock consolidates after recent gains as investors watch pipeline progress
Relay Therapeutics stock recently consolidated below its 52-week high after a rally, closing at USD 18.84 on September 18, 2026. The clinical-stage biotechnology company's valuation is anchored by its cash reserves, which fund R&D and support its pipeline for several years, despite operating expenses exceeding revenue. Investors are closely monitoring upcoming pipeline updates and clinical trial outcomes, as these will likely determine the stock's future trajectory given the company's reliance on a limited number of late-stage assets.